Diabetes Archives

News and Trends 13 Jun 2016

Italy cures Diabetes with new Engineered Mini-organs

Ospedale Niguarda Ca’ Granda has succeeded in treating a patient with type 1 diabetes, using a new tissue engineering techniques for more effective islet transplants – something that could bring this diabetes cure to more patients. Biotech is tackling diabetes from several fronts – from mitigation of symptoms, for example, Avita’s skin spray, to medtech inventions […]

June 13, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 2 Jun 2016

A ‘Skin Spray’ could cure Chronic Skin Wounds caused by Diabetes

Avita has initiated a trial in the UK to evaluate the potential of its ReGenerCell technology to treat diabetic foot ulcers, a skin wound that can be very hard to treat. With offices in the UK and originally from Australia, Avita Medical is developing products in tissue engineering and regenerative medicine. Its technology utilises the […]

June 2, 2016 - 2 minutesmins - By Denise Neves Gameiro

roche diabetes senseonics fluorescent sensor

News and Trends 30 May 2016

Roche debuts new MedTech for needle-free management of Diabetes

Roche is making progress in its Diabetes Care unit. It has struck a deal with the MedTech company Senseonics to sell an implantable glucose sensor in some major European countries. The Diabetes Care division of Swiss big Pharma Roche has more than 35 years of experience, and its Accu-Check devices are one of best-selling diabetes management […]

May 30, 2016 - 2 minutesmins - By Denise Neves Gameiro

diabaetes insulin biotech islexa catapult uk trials aberdeen

News and Trends 18 May 2016

New UK Biotech could treat Diabetes with Lab-grown Cells

Islexa is the new baby of Catapult and the University of Aberdeen, which will be developing laboratory grown islets. This could replace insulin production in patients with type 1 diabetes. One of the coolest Biotechs in London, Catapult has joined the University of Aberdeen to create a new Biotech that could revolutionize treatment of type […]

May 18, 2016 - 3 minutesmins - By Denise Neves Gameiro

cellnovo biotech diabetes medtech device horizon2020

News and Trends 13 Apr 2016

Mobile Pancreas to Change Life of Diabetics in New EU Programme

A new €4M European project brings a mobile insulin pump from France, computer models from Romania, and research from the UK & Spain together, in order to improve living with diabetes. Cellnovo, a MedTech split between France and the UK, was selected to participate in a new diabetes project funded by Horizon 2020, the EU grant […]

April 13, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 11 Dec 2015

Biotech of the Week: Zealand Pharma, Biotech Success Story made in Denmark

This week we say farewell to Zurich and head North, through Germany where we arrive at our next destination, the capital city of Denmark, Copenhagen. This amazing city is famous for the Little Mermaid Statue, the autonomous neighborhood of Christiania and Tivoli Gardens Amusement Park. It is also home to our biotech of the week: Zealand […]

December 11, 2015 - 2 minutesmins - By Philip Hemme

cytotools medday stock black friday drop phase III fail

News and Trends 4 Dec 2015

Black Friday Ruin as TWO Biotechs Fail in Phase III Trials

A shocking Black Friday for these two Biotechs: Both CytoTools (Germany) and MedDay (France) phase III trials in chronic disease flopped massively, and stocks dropped as much as 85% in one day… Multiple Sclerosis Headliner, MedDay’s MD1003, has flopped in its phase III trial after failing to meet its primary endpoint. This is a disastrous […]

December 4, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 26 Nov 2015

Ablynx Top Trumps: Adding Danish Diabetes Giant Novo Nordisk to its Biotech Deck

Ablynx – the Belgian Nanobody biotech (which uses monoclonal antibodies of Alpacas) has entered a new and exclusive partnership with the Danish Novo Nordisk on a mysterious disease… Ablynx are famously well connected in the biotech industry, with many huge pharmas licensing out their Alpaca-nanobody tech. Partnerships include AbbVie (Immunology), Boehringer Ingelheim, Genzyme (Multiple Sclerosis/CNS), […]

November 26, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 12 Oct 2015

A Sweet idea from Napoli; An Italian start-up will renovate the Artificial Sweetener market

Monellin chain B is an artificial sweetener initially mistaken for a carbohydrate. It has since been established to actually be a natural protein based sweetner which is fairly unstable. iSweetch from the University of Naples has used E. Coli to engineer a more stable version of the protein to revolutionize the artificial sweetner industry. Monellin […]

October 12, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 18 Sep 2015

Servier to revolutionize Diabetes treatment thanks to Intarcia’s successful Phase III

Treatment of diabetes hasn’t changed so much since the development of first human insulin by Genentech. But Boston-based Intarcia (a partner of Servier and one of the 9 billion-dollar Biotech startups worldwide) has just published positive phase III results of its implantable device aiming at changing how type 2 diabetes are treated. November 2014: I thought […]

September 18, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 16 Sep 2015

Giving new life to Sanofi’s annual €6.2Bn diabetes blockbuster Lantus

Sanofi has announced positive results of its combination drug LixiLan phase III trials for Type 2 diabetes. Constituted from both Lixisenatide and insulin glargine Lantus, LixiLan is developed to tackle type 2 diabetes when both oral medication fails and basal insulin loses its efficacy. Lixisenatide (Lyxumia outside the US) was initially discovered by Zealand […]

September 16, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 10 Sep 2015

Genkyotex’ NOX inhibitor candidate Fails to follow through on Phase II

The French biotech Genkyotex has announced Phase II results for GKT137831 in diabetic kidney disease. The NOX1-4 inhibitor failed to reduce albuminuria. Genkyotex focuses on developing inhibitors of nicotinamide adenine dinucleotide phosphate-oxidase (NADPH) enzymes which are expressed by the NOX-gene family (NOX 1-5). NOX enzymes generate reactive oxidative species (ROS) which if overproduced, can cause […]

September 10, 2015 - 2 minutesmins - By Dani Bancroft

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us